Creative Frontend Developer ⚡ Crafting cinematic, Awwwards-level UIs. Mastering JS, GSAP & WebGL ️ React & Tailwind. Fueled by clean code & good cinema 🎬🍃 ...

We've tested the top AI image generation apps to help you find the one that produces the best results for the lowest price. I’ve been writing about consumer technology and video games for more than a ...

So, you want to get better at those tricky LeetCode Python problems, huh? It’s a common goal, especially if you’re aiming for tech jobs. Many people try to just grind through tons of problems, but ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

AI drug discovery specialist Generate Biomedicines has raised $400 million in the year’s largest initial public offering to date for a biotechnology firm. The company, which was launched in 2018 by ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate is indicative of a more mature startup that may have a better chance of succeeding in today’s markets. Industry IPOs peaked in 2021, resulting in a flood of companies whose early science didn ...

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...